Industry leaders launch Actionable Genome Consortium
SAN DIEGO—Illumina Inc. and four leading cancer centers have established the Actionable Genome Consortium (AGC), an initiative that will recommend openly published standards for widespread use of next-generation sequencing to aid in treatment decision for cancer patients. Specifically, the AGC will aim to define the principles and content of the “cancer actionable genome,” a comprehensive description of genomic alterations that define individuals’ tumors. The founding members include, other than Illumina, the Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. The AGC will publish a list of actionable events—including best practices regarding biopsy samples, performance standards for sequencing, guidelines for clinical reports and standards for genetic variants—and include a research arm for collaborative, cross-institutional projects regarding leading challenges in molecular oncology.